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Alzheimer’s disease (AD), a progressive neurodegenerative disorder that affects mostly the 
limbic system and the neocortical areas of the brain, is the most prevalent form of dementia 
affecting the elderly population. Twenty-nine million people live with the disease worldwide, 
10% of the population > 65 years of age and 50 % of the population > 85 years of age. These 
figures are expected to increase exponentially over the next few decades and reach 81.1 million 
by the year 2040.  Hallmark lesions include extracellular deposition of β-amyloid protein (Aβ) 
fibrillar plaques and intraneuronal neurofibrillary tangles (NFTs), which impair synaptic 
plasticity in the target regions of the brain thereby producing a progressive decline in cognitive 
function, with the earliest signs observed in learning and memory. Current therapies of AD are 
merely palliative and only slow down cognitive decline. In a recent study a novel compound, 
poly-N-methylated amyloid beta (Aβ)-peptide C-terminal fragments (MEPTIDES) was shown to 
reduce Aβ toxicity in vitro and in Drosophila melanogaster, however whether this novel drug is 
equally effective in mammals to inhibit Aβ-induced toxicity remains unclear. Accordingly in the 
present study we investigated the effects of MEPTIDES on the neurotoxicity induced by a single 
intracerebral (i.c.) injection of Aβ42 into the dorsal hippocampus of adult male Sprague-Dawley 
(SD) rats, a model of AD-like impaired learning and memory, and explored the implications of 
these findings for possible future management therapies or AD. 
 Methods 
Ethical clearance (ref: 048/13/Animal) was obtained from the University of KwaZulu-Natal 
Ethics Committee. Fully grown male SD rats (n = 40, 300 - 350 g, 8 - 9 weeks of age at the 
beginning of the study) were used. The study was divided into 2 parts. In part A, a rat model (n = 
20) of impaired learning and memory was established using Aβ42 (2 mM). A total of 100 µg of 
the neurotoxin was injected bilaterally into the dorsal hippocampus at a rate of 1 µl/ minute. In 
part B, the effect of MEPTIDES (2 mg/kg) injected intraperitoneally (i.p.) on Aβ42-induced 
neurotoxicity was investigated in vivo (n = 20). Control rats received intra-hippocampal 
injections of vehicle (Tris buffer, TB, 0.15 M). Learning and memory tests were performed using 




Aβ42.  Caspase 3 (C3), Tumor Necrosis factor Alpha (TNF-α), and 4-Hydroxynonel (4HNE) 
levels were measured in hippocampal tissue by either qPCR, Western Blot, or ELISA. MALDI 
TOF MS was used to determine whether MEPTIDES cross the blood brain barrier (BBB) and 
their distribution in the rat brain thereof. 
Results 
Behavioural results showed spatial learning and memory deficits in rats that were injected with 
Aβ42. These animals also displayed upregulation of C3 in the dorsal hippocampus. These effects 
were reversed in the rats that received i.p. injections of MEPTIDES, 24 hours after intra-
hippocampal injection of Aβ42. C3 cascade disruptions appeared to be amongst the earliest 
markers of Aβ42-induced neurotoxicity. 
Discussion and Conclusion 
Findings from this study showed that a single i.c. injection of Aβ42 induces C3 cascade and 
behavioural deficits in an adult male SD rat.  i.p. injections of MEPTIDES, 24 hours after intra-
hippocampal injection of Aβ42 reversed these effects. 
 

















1.0  Preamble 
 Alzheimer’s disease (AD) is a poly-aetiological neurological disorder that leads to dementia 
(Sipos et al., 2007). The disease hallmarks include extracellular deposition of amyloid-β 
protein (Aβ) and intraneuronal neurofibrillary tangles (NFTs). The earliest symptoms include 
learning and memory deficits (U.S. Alzheimer’s Association, 2011). A novel compound, 
MEPTIDES, which is synthesized from C-terminal fragments of Aβ (covering residues 31 - 
42 or parts thereof), has been shown to reduce toxicity of Aβ in vitro and in Drosophila 
melanogaster (Pratim Bose et al., 2009), but it’s effects on Aβ neurotoxicity in vivo still 
remain elusive. Accordingly, this study investigated the effects of MEPTIDES in vivo on 
Aβ42-induced neurotoxicity in an adult male Sprague-Dawley (SD) rat model of learning and 
memory, which may have implications for AD management and treatment therapies.  
 
 
1.1   Introduction 
AD is a progressive neurodegenerative disorder that affects mostly the limbic system and the 
neocortical areas of the brain (Sipos et al., 2007). AD presents clinically as an inexorable 
cognitive impairment and a significant decline in performance of activities of daily living as 
it progresses. AD is the most prevalent form of dementia affecting the elderly population 
(U.S. Alzheimer’s Association, 2011). Females are more prone to suffer from AD than males 
due to differences in hormonal profiling (Mathew et al., 2011), even after correcting for 
differences in life expectancies (Kumar et al., 2011). AD is associated with a number of risk 
factors which include aging, family history, apolipoprotein E4 (ApoE4), 
hypercholesterolaemia (Huang et al., 2007), diabetes, hypertension, high alcohol intake  and 
vascular diseases (Findeis, 2007). Data show that 29 million people live with the disease 
worldwide (Reddy, 2011), 5.4 million in the U.S. alone (U.S. Alzheimer’s Association, 
2011), and these figures are expected to increase exponentially over the following decades 
(U.S. Alzheimer’s Association 2011; Cole and Vassar, 2007) and reach 81.1 million by the 
year 2040 (Chu, 2012). 
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1.2  Classification of Alzheimer’s disease 
There are basically 2 forms of AD. One is early onset Familial Alzheimer’s  disease (FAD) 
which is caused by autosomal dominant mutations in either Amyloid Precursor Protein (APP) 
or Presenilin 1 or 2 (PS1/PS2) genes (Mathew et al., 2011). FAD accounts for approximately 
2% of all AD cases. Mutations in these genes may cause an increase or decrease in the 
production of Aβ42 (Findeis, 2007), an increase in the production may lead to 100% 
penetrance of the disease (Cole and Vassar, 2007). Presenilin 1 gene mutations are the most 
common among FAD mutations (Chu, 2012). The second form is late onset Sporadic 
Alzheimer’s disease (SAD) which accounts for approximately 98% of all AD cases and the 
underlying causes of this AD type remain elusive (Mathew et al., 2011).  
 
It is estimated that the costs for dementia care worldwide are in the region of 315.4 billion 
U.S. Dollars annually (U.S. Alzheimer’s Association, 2007). In 2012, the total worldwide 
societal cost of dementia was estimated to be US$ 422 billion (Chu, 2012). Blocking disease 
progression or, in the best case scenario, preventing AD altogether would not only have 
significant benefits to the patient and their families, but would also substantially lighten the 
enormous economic burden to the community at large. Since the majority of AD cases arise 
from sporadic causes, the bulk of scientific investigations have thus focused on this dementia 
type.  
 
1.3 Aetiology of AD 
AD has 2 hallmark lesions namely, extracellular deposition of Aβ protein fibrillar plaques 
and intraneuronal NFTs (Mamelak, 2007), but it still remains unclear whether these are the 
cause of AD (Heneka and O'Banion, 2007). Evidence suggests that altered metabolism is a 
very early change in AD and that oxidative stress, particularly in lipids, proteins and DNA 
(Irie et al., 2005) of vulnerable neurons (Mamelak, 2007), precedes plaque formation 
(Gibson, 2002). Aβ has been shown to disrupt calcium (Ca
2+
) homeostasis by increasing the 
density of L and N-type voltage-dependent Ca
2+
 channels (Freir et al., 2003) and enhancing 
the influx of Ca
2+
 into hippocampal neurons through these channels. This suggests that Ca
2+
 
channels may play a role in the pathogenesis of AD (Freir et al., 2003). Additional 
neuropathologies include reactive microglial cells, increased expression of apoptotic protein 
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features, dystrophic neurons and bundles of astrocytic processes (Mamelak, 2007) as well as 
cholinergic, dopaminergic and serotonergic dysfunctions (Mandel et al., 2007).  
 
1.4 Neurofibrillary tangles (NFTs) 
NFTs consist of paired helical filaments that are composed of abnormally 
hyperphosphorylated microtubule-associated tau protein (Fen et al., 2010). Tau is 
predominantly expressed in neuronal axons (Reddy, 2011), and has more than 30 
phosphorylation sites. Tau phosphorylation regulates microtubule assembly and plays a role 
in the outgrowth of neuronal processes, regulation of the intricate transport system of the 
neuron, and the development of neuronal polarity (Reddy, 2011). In contrast, 
hyperphosphorylated tau becomes pathological destabilizing microtubules, resulting in the 
aggregation of hyperphosphorylated tau (Reddy, 2011). Increased evidence suggests that tau 
is critically involved in AD pathogenesis, particularly in impairing axonal transport of APP 
and subcellular organelles including mitochondria in neurons affected by AD (Reddy, 2011). 
Recent data reviewed by Reddy (2011) demonstrated that Aβ production, accumulation and 
Aβ-induced oxidative stress are critical factors for the hyperphosphorylation of tau in AD 
neurons, which ultimately leads to the production of NFTs. Neurons with NFTs show 
extensive oxidative stress, suggesting that oxidative stress plays a vital role in the 
pathophysiology of AD (Gibson, 2002). NFTs are arguably the most important aspect of the 
degenerating phenotype in AD-affected neurons (Perry et al., 2002). 
 
1.5  Models of AD  
Genetics play an important role in the manifestation of AD and AD-associated genes, which 
may be divided into those in which mutations cause autosomal dominant AD and those which 
polymorphisms serve as risk factors for AD, have paved the way for the development of AD 
mouse models (Hall and Roberson, 2012). The oldest and most commonly used transgenic 
models based on the expression of human APP (hAPP) have contributed enormously to the 
testing of the Amyloid hypothesis, several therapeutic agents and more recently, biomarkers 
that can assist in the detection of asymptomatic AD (Hall and Roberson, 2012).  
Traditionally, mice have been chosen over rats for transgenesis owing to technical reasons, 
but rats offer more advantages than mice because their lineage is closer to that of humans in 
several physiological and functional aspects (Hall and Roberson, 2012). The range of 
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advantages that rats offer include, larger body surface area and brain size which facilitate 
intracerebral administration of different experimental compounds as well as neurosurgical 
and neuroimaging experiments. The major advantage that rats offer is behavioural 
characterization because of their finer motor coordination when compared to that of mice 
(Hall and Roberson, 2012). A complete model of AD would have to display the full spectra 
of the underlying clinical and pathological symptoms of AD, no presently existing model 
exhibits all the features of AD, existing models develop phenotypes of AD to different 
extents and combinations (Hall and Roberson, 2012). The model of bilateral i.c. injections of 
Aβ42 into the dorsal hippocampus of a rat brain that we used in the present study was adopted 
from a study done by Shin et al. (1997), and was modified to answer specifically, the 
questions that were asked by our study. 
 
1.6 Aβ homeostasis  
APP processing is found to be somewhat heterogeneous, resulting in the production of 
variable lengths of Aβ, particularly at the carboxyl terminus (Cole and Vassar, 2007). The 
two major forms of Aβ that have been observed to be produced in the processing of APP are, 
40 and 42 residues in length, Aβ40 (produced as a cellular antioxidant) and Aβ42 (has been 
shown to be neurotoxic), respectively (Findeis, 2007). In a normal individual, the majority of 
the Aβ produced is of the shorter variety, Aβ40 (Cole and Vassar, 2007). Cerebral Aβ levels 
are regulated by the production, clearance and degradation of Aβ (Reddy, 2011). APP 
metabolism may also play a role in tau phosphorylation and subsequent NFT formation 
(Cetin, 2013). 
 
1.6.1     Amyloid Precursor Protein (APP) 
APP is a type-I transmembrane protein that has 695-770 amino acids (AAs) (Mathew et al., 
2011). It is transported from endoplasmic reticulum (ER) to the cell surface via a secretory 
pathway and has a large extracellular hydrophilic N-terminus, and a small cytoplasmic C-
terminus (Mathew et al., 2011). The APP gene is located on chromosome 21 and mutations in 





1.6.2 Secretase enzymes  
β-Secretase is a novel aspartyl protease known as β-site APP-cleaving enzyme (BACE1) 
(Cole and Vassar, 2007), a type-I membrane protease with 501 AAs from the pepsin-like 
class of protease enzymes (Barman and Prabhakar, 2013). It is the rate-limiting enzyme in the 
synthesis of Aβ and therefore the prime drug target for lowering cerebral Aβ levels in the 
management, treatment and prevention of AD (Cole and Vassar, 2007). γ-Secretase is a 
complex of proteins consisting of presenilin 1 or 2 (PS1/PS2), nicastrin, anterior pharynx-
defective 1 (Aph1) and presenilin enhancer 2 (Pen2). α-Secretase is TNF-α converting 
enzyme (TACE), a member of the disintegrin and metalloprotease domain protein (ADAM) 
family (Cole and Vassar, 2007). 
 
BACE1 utilizes the general acid base mechanism to cleave the peptide bond during its 
catalytic cycle (Barman and Prabhakar, 2013). It initiates synthesis in the amyloidogenic 
pathway at the Asp+1 residue of APP to form the N-terminus of Aβ. The scission results in 
two cleavage fragments, a secreted APP ectodomain (APPsβ) and a membrane bound 
carboxyl terminal fragment (CTF) that is subsequently cleaved by γ-secretase to generate the 
C-terminus of Aβ and an APP intracellular domain (AICD) which is released into the cytosol 
(Cole and Vassar, 2007), and thus migrates to the nucleus (Mathew et al., 2011) where it 
plays a role in transcriptional transactivation (Cole and Vassar, 2007) by regulating 
phosphoinositide-mediated Ca
2+
 signaling through a γ-secretase-dependent signaling pathway 
(Findeis, 2007).  
In the alternate non-amyloidogenic pathway, α-secretase cleavage occurs within the Aβ 
domain at Leu+17 residue of APP. The scission produces a secreted (APPsα) ectodomain and 
a CTF which in turn is cleaved by γ-secretase to form a 3kDa fragment p3 (Cole and Vassar, 
2007). APPsα activates a putative receptor on the neuronal membrane which initiates a series 
of reactions that lead to the opening of potassium (K
+
) channels (Mathew et al., 2011). This 
ultimately leads to the activation of nuclear transcription factor kappa β (NFkβ), which 




Key: N/C – N/C-terminus of APP, APP – Amyloid precursor protein, Aβ – Amyloid beta, β/α/γ –
Beta/Alpha/Gamma secretase enzymes, AICD – APP intracellular domain 
 
Figure 1.1: Diagram showing APP cleavage by secretase enzymes in the amyloidogenic/non - 
amyloidogenic pathways. Image adapted from Cole and Vassar (2007).  
 
Although the majority of body tissues exhibit β-secretase activity, the highest levels are 
observed in neuronal cell lines and brain tissue with optimal activity detected at an acidic pH 
of 4.5 within subcellular compartments of the secretory pathway (the trans-Golgi network 






1.6.3  Aβ Pathology 
Aβ42 is a 4kDa (Mathew et al., 2011) amphiphilic protein (Bose et al., 2009), that accounts 
for about 5-15 % of the total Aβ pool in a normal individual (Findeis, 2007). It is generated 
following abnormal sequential cleavage of the transmembrane APP by β- and γ-secretase in 
the amyloidogenic pathway (Fen et al., 2010), (see figure 1.1). The Aβ42 protein subsequently 
aggregates and forms higher order oligomers that directly interact with the cell membrane 
through the receptor for advanced glycation end products (AGEs) (Behl and Moosmann, 
2002) but the molecular mechanisms underlying the generation of soluble oligomers, 
insoluble fibrils, other neurotoxic species and their aggregation (Crews et al., 2010) are not 
fully understood (Bose et al., 2009). Synthesis of Aβ42 is precluded if APP is cleaved by α-
secretase within the Aβ domain in the non-amyloidogenic pathway. β- and α-Secretase 
moieties compete for APP substrate and hence an increase in the amyloidogenic pathway is 
coupled with a reciprocal decrease in the non-amyloidogenic pathway and vice versa (Cole 
and Vassar, 2007). 
 
In this study we particularly focused on oxidative stress, apoptosis, and inflammation 
mediated by stereotaxic infusion of Aβ42 into the dorsal hippocampus of an adult male SD rat 
model of learning and memory. We also investigated the effectiveness of MEPTIDES in vivo 
in the prevention and/or reduction of Aβ-induced neurotoxicity which may support 
MEPTIDES as a possible anti-AD drug which is beneficial in preventing or slowing down 
cognitive decline.   
 
1.7 Inflammation 
While minor signs of neuroinflammation can be found in a normal aging brain, the AD brain 
displays increased activation of inflammatory systems suggesting that qualitatively different 
immunostimulants may exist in the latter (Heneka and O'Banion, 2007). Although synthesis 
and deposition of Aβ and NFTs are hallmarks of AD (Mamelak, 2007, Heneka and O'Banion, 
2007), evidence suggests that inflammation in pathologically vulnerable regions of the AD 
brain (Akiyama et al., 2000) represents the third hallmark (Heneka and O'Banion, 2007). 
Damaged neurons and neurites and highly insoluble Aβ peptide deposits and NFTs provide 
stimuli for inflammation in the AD brain (Akiyama et al., 2000). Microglia represent the 
innate immune system in the brain and express a wide array of receptors that detect foreign 
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particles and tissue damage (Cameron and Landreth, 2010). Toll-like receptors (TLRs) are 
the most prominently expressed receptors in microglia, with TLR 2, 4 and TLR co-receptor, 
CD14, being of importance in AD (Cameron and Landreth, 2010). Following activation, 
various neuro-inflammatory (pro and anti-inflammatory) mediators, including a wide array of 
neurotoxic cytokines and chemokines are produced and released by microglia, which may 
also result in recruitment of astrocytes and neurons to the inflammatory response, and this 
cascade is thought to actively enhance the inflammatory response to extracellular Aβ plaques 
(Heneka and O'Banion, 2007). Astrocytes are involved in the degradation and clearance of 
Aβ, and provide trophic protection of neurons by forming a protective barrier between 
neurons and Aβ plaques (Heneka and O'Banion, 2007). Increased astrocyte number 
associated with Aβ lesions in AD suggests that these aggregates produce chemotactic 
molecules that recruit astrocytes (Heneka and O'Banion, 2007). Once this inflammation is 
initiated by degeneration, it may significantly contribute to disease progression and chronicity 
(Heneka and O'Banion, 2007).  
While inflammation is thought to be secondary to degeneration, evidence suggests that 
microglia and astrocytes (Heneka and O'Banion, 2007) may be activated by endogenous 
proteins which increase the production of inflammatory cytokines (Heneka and O'Banion, 
2007) like Interleukin-1β (IL-1β), Tumor necrosis factor alpha (TNFα) (Rogers et al., 1996) 
which regulate the intensity and duration of the inflammatory response (Heneka and 
O'Banion, 2007). In AD these have been observed to enhance APP processing by 
upregulating β-Secretase, altering Aβ fibrillar protein production and/or metabolism (Rogers 
et al., 1996) therefore increasing neurotoxic secretory products, pro-inflammatory cytokines 
and ROS (Eikelenboom and van Gool, 2004) which  establishes a vicious cycle (Heneka and 
O'Banion, 2007) that greatly contributes to neuronal damage. TNF-α, a pro-inflammatory 
cytokine and a focus in the present study, exhibits both pro-apoptotic and anti-apoptotic 
properties that account for the majority of the neurotoxic effects of proteins secreted by 
microglia in the CNS (Heneka and O'Banion, 2007). Nearly all cytokines that have been 
studied in animal models of AD, primarily in immunohistological evaluations, including IL-
1β, IL-6 and TNFα were upregulated when compared to their control equivalents (Akiyama 
et al., 2000). These differences are less likely to be a result of genetic polymorphisms that 
have been previously described (Nicoll et al., 2000, Papassotiropoulos et al., 1999, McCusker 
et al., 2001) because none of the members of the cytokine family that are associated with AD 
map onto the chromosomal region with evidence of a genetic linkage (Tanzi and Bertram, 
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2005) that increases the risk of AD development later in life. In an article by Akiyama et al. 
(2000), TNFα was reported to be neuroprotective in the AD brain.  It is this controversy that 
inspired our research team to investigate whether TNFα is up or downregulated in our animal 
model of Aβ-induced memory impairment and to subsequently establish what the 
implications of these changes are. 
 
1.8      Oxidative stress  
Reactive oxygen species (ROS) play an important role in the regulation of normal cellular 
and thus body function when they are produced at low concentrations at the appropriate time 
and place but when they are produced in excess, they can have detrimental consequences 
particularly for mitochondrial function and ultimately cellular integrity, a state known as 
oxidative stress (Rosenfeldt et al., 2013). ROS may target any cell component, but they 
generally react with the first structure they encounter, which is frequently the lipid bilayer of 
cell membranes. Oxidative stress represents an imbalance in the production of ROS and the 
body’s antioxidant defense system’s ability to detoxify the reactive intermediates (Rosenfeldt 
et al., 2013). The body has developed natural defense systems such as endogenous 
antioxidants that counteract the destructive effects of ROS and maintain REDOX equilibrium 
thus ensuring optimal health (Perry et al., 2002). Various intrinsic enzymatic and non-
enzymatic pathways are involved in achieving this REDOX equilibrium (Perry et al., 2002).  
The cytopathological significance of oxidative damage is seen by the upregulation of anti-
oxidant enzymes (Mamelak, 2007). Sources of ROS include enzymatic activation of 
cytochrome C, NADPH oxidases, xanthine oxidase, dysregulation of endothelial nitric oxide 
synthase (eNOS) and leakage from mitochondria.  The brain is a logical target for free radical 
damage due to its high concentration of unsaturated lipids, catecholamines and increased rate 
of oxidative metabolism (Mamelak, 2007, Lee et al., 2012). The brain also has low 
concentrations of enzymatic antioxidants and non-enzymatic free radical scavengers, whilst 
certain areas contain large amounts of iron (Fe) which is a crucial cofactor in ROS generation 
(Mamelak, 2007). This suggests that oxidative stress contributes to brain aging, but is by no 
means the sole cause of brain senescence (Mamelak, 2007).  
Oxidative insults that induce neuronal apoptosis, including agents that induce membrane lipid 
peroxidation, have been shown to activate caspases (Cetin, 2013). Damage caused by 
oxidative radicals observed in AD includes AGEs, nitration, lipid peroxidation adduction 
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products as well as carbonyl-modified neurofilament protein and free carbonyls (Mamelak, 
2007). This damage involves all neurons vulnerable to death in AD and not only those 




 channels and 
glucose uptake which leads to apoptosis (Mathew et al., 2011). The free radical theory of 
ageing proposes that, prolonged pro-oxidant status generated during normal cellular 
metabolism causes cumulative damage to DNA and other macromolecules (Mamelak, 2007). 
It also suggests that free radicals and their reactions are involved in the aetiology and 
development of a number of life-limiting diseases (Mamelak, 2007). Increased mitochondrial 
DNA in the early stages of AD may be linked to increased oxidative potential (Mamelak, 
2007). Haem oxygenase (HO-1) is among the most sensitive indicators of the cellular 
oxidative stress response and it has been shown that both HO-1 and its mRNA are increased 
in the brains of patients with AD (Mamelak, 2007). In a review by (Mamelak, 2007) it is 
suggested that increased HO-1 expression co-localizes with the altered form of tau protein. 
The most crucial aspect of oxidative damage in AD pathogenesis appear to be the 
cytoskeletal modifications (e.g. NFTs, are the most obvious modification and are the 
important phenotype in a degenerating neuron) in neurons that are susceptible to damage in 
AD, which in turn plays a key role in the irreversible cellular dysfunctions that ultimately 







Figure 1.2: Diagram showing how several conditions including Aβ aggregation may lead to 
increased oxy-radicals resulting in membrane lipid peroxidation and generation of lipid 
peroxidation adducts like 4HNE that increase intracellular Ca
2+ 
levels that may cause a 




Apoptosis is a highly regulated process involved in embryonic development, developmental 
tissue remodeling, normal cell turnover and is a cell death program central to cellular and 
tissue homeostasis (Cetin, 2013). Apoptosis is increased in the aging process due to increased 
oxidative stress (Cetin, 2013) and is characterized morphologically by a series of events that 
include cytoplasmic shrinkage, chromatin condensation, nuclear and cellular fragmentation, 
and the formation of apoptotic bodies. Dysregulation in apoptotic pathways results in 
excessive or insufficient cell death that may result in several pathological processes leading 
to disease states such as cancers, autoimmune syndromes and/or neurodegenerative diseases 
like AD.  
Caspases are a family of intracellular cysteine-aspartate proteases that are divided into 
initiators of apoptosis (caspases-2, -8, -9 and -10), and effectors of apoptosis (caspases-3, -6, 
-7 and -14), however some caspases, including caspase-3 (C3) and caspase-6 (Casp6), appear 
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to function as both initiators and effectors (Cetin, 2013). Caspases are not only essential for 
triggering apoptosis, they have also been shown to play key roles in other non-apoptotic 
pathways, such as differentiation and proliferation of diverse cell types, axon guidance and 
synaptic activity and plasticity (Cetin, 2013). Activation of caspases has been implicated in 
several neurodegenerative diseases, such as AD, Huntington’s disease (HD), various ataxias 
and amyotrophic lateral sclerosis (Cetin, 2013).  
Cells undergo apoptosis through two major pathways, the extrinsic pathway (death receptor 
pathway) (Zeng et al., 2012) and the intrinsic pathway (the mitochondrial pathway) (Romani 
et al., 2010). These two pathways can be linked by caspase-8-activated truncated Bid 
formation. Very recently, death receptor 6 (DR6) also known as TNFRSF21, a relatively new 
member of the death receptor family was shown to be involved in the neurodegeneration 
observed in AD (Zeng et al., 2012). It was found that DR6 induces apoptosis when it is 
overexpressed (Zeng et al., 2012). However, how the death signal mediated by DR6 is 
transduced intracellularly is not known. Although caspases are the main players involved in 
apoptosis, there are other molecules involved in the progression of the apoptotic cascade that 
are relevant to AD (Cetin, 2013).  
 
Figure 1.3: Diagram showing intracellular sources of ROS and their interaction with 




Figure 1.4: Diagram showing nitric oxide (NO) neurotoxicity in relation to AD.  
NFT formation may influence Aβ accumulation and vice versa that leads to cell death 
secondary to disruption of cellular trafficking. Cholinergic deficit is one of the most 
significant findings in AD, and is implicated in memory impairments observed in this 
disease. Increased production of Aβ induces NO production either by disrupting Ca
2+ 
homeostasis and subsequent increase in intracellular Ca
2+
 (nNOS and eNOS-mediated NO 
release) or by interactions with glial cells. These reactive oxygen species induce a variety of 
neurotoxic mechanisms, including DNA/protein alterations, mitochondrial dysfunction, 
apoptosis, neuro-inflammation, and lipid peroxidation (which jeopardize cellular membrane 
integrity, which leads to further Ca
2+
 influx and NO release). These mechanisms are likely to 
be involved in cell death and memory impairments observed in AD (Cetin, 2013). 
Neuronal death in AD may result directly and/or indirectly from the triggering insults caused 
by Aβ toxicity, glutamate excitotoxicity, long-lasting oxidative stress, DNA damage, and 
elevation of intracellular Ca
2+
 levels. Thus, the mode of cell death in AD remains a matter of 
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controversy, and it is possible that both apoptotic and non-apoptotic cell death coexist in the 
brains of affected patients.  
 
1.10 Manifestations of AD 
Depending on the subtype of the disease, manifestations may either include or lead to 
behavioural changes or vascular diseases (Breteler, 2000). The amyloid cascade hypothesis 
suggests that  early aggregation of Aβ triggers a complex of pathological cascades that lead to 
neurodegeneration with loss of working/short term memory as early symptoms (Fen et al., 
2010) of disease manifestation. Methionine residue number 35 (Met 35) and neighbouring 
residues of Aβ are apparently important in this early aggregation (Pratim Bose et al., 2009). 
On the other hand, the cholinergic hypothesis proposes that it is the decrease in synthesis of 
the neurotransmitter acetylcholine that is the cause of AD (Bayer and Wirths, 2010). 
In the vast majority of late-onset SAD, the majority of evidence collected does not support 
the amyloid cascade hypothesis as it is considered too narrow to explain all of the molecular 
mechanisms that lead to the characteristic accumulation of the neuropathological hallmarks 
of the disease (Simic et al., 2009). It is therefore not surprising that treatments aimed at 
lowering Aβ aggregation and production failed to show clinical improvement in AD patients. 
It is therefore necessary to gain a better understanding of the molecular and cognitive effects 
of different Aβ forms (Sipos et al., 2007) in order to design better therapeutic interventions 
targeting the Aβ cascade. 
AD affects people differently. The most common symptom found among all patients is 
forgetfulness of new information. Over time, the disease progresses and reaches an 
irreversible level where the patient is unable to perform basic daily life activities such as 
bathing, dressing or eating (Mandell and Green, 2011). At the late stage of the disease, the 
patient cannot even move, communicate or recognize family members. The Patient then 
becomes vulnerable to infection which may be fatal. Clinically AD is characterized by 
cognitive decline and memory loss (Allison et al., 2001). Although mild cognitive 
impairments (MCI) represent the harbinger signs of the disease, patients with MCIs do not 
always develop AD. The presence of Aβ plaques in the cortex and NFTs mark the advanced 
level of AD (Madsen et al., 2010). Biochemical events including loss of neurons and 
15 
 
synapses in specific regions of the brain lead to the development of the disease and these are 
life-threatening. 
 
1.11 Diagnosis  
Historically diagnosis of AD was made after exclusion of all other possible causes of 
dementia, including metabolic imbalances such as vitamin deficiencies or other neurological 
disorders with more definitive diagnostic criteria (Findeis, 2007). Problems associated with 
AD and other neurodegenerative disorders arise from the fact that cognitive tests currently 
used to assess clinical benefit of symptomatic drug treatment might suffer subjectivity and 
little sensitivity to subtle changes over time (Deguil et al., 2013). The other problem is that no 
equivalent task exists for research animal models as the verbal component, which is primarily 
used in these tests, is lacking in animals (Deguil et al., 2013).  
A clinical diagnosis of AD is made when patients have progressive memory decline for over 
6 months with resultant impairment of self-care and social or occupational functioning (Chu, 
2012), but this is still limited to probable or possible AD (Findeis, 2007). The presence of 
objective memory impairment should be documented by the Mini-Mental State Examination 
(MMSE) and other neuropsychological tests (Chu, 2012). Diagnosis of definite AD continues 
to require postmortem histological analysis of the brain to document the presence of 
characteristic senile plaques and tangles that define the disease (Findeis, 2007). The 
importance of the Aβ40/Aβ42 ratio emerged in examinations of both CSF and plasma of 
humans with or without AD and other neurodegenerative diseases (Findeis, 2007). Unlike 
other diagnostic methods that image brain function and/or volume, the Aβ40/Aβ42 ratio offers 
an opportunity to identify individuals at an even earlier pre-symptomatic stage of the disease 
(Findeis, 2007). Such individuals could then be placed on therapy that can potentially slow or 
prevent disease progression at a stage of disease where the efficacy of the treatment can be 
expected to be much greater than in patients at a more advanced stage of the disease (Findeis, 
2007). 
Other essential diagnostic points include deficits in two or more areas of cognition, absence 
of disturbance in consciousness, disease onset between the ages of 40 and 90 years, absence 
of systemic disorders or other brain diseases that could account for the progressive deficits in 
memory and cognition, evidence of cerebral atrophy on computed tomography (CT) or 
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magnetic resonance imaging (MRI) scans without other significant organic lesions, and the 
absence of any metabolic disorder. 
 
1.12 Conventional management strategies 
Current therapies of AD are merely palliative and only slow down cognitive decline. 
Treatments which address underlying pathologic mechanisms are completely lacking. 
Regular exercise, higher education and proper diet have been reported to be protective, as has 
smoking, despite its other negative health effects (Findeis, 2007). Other experimental 
therapies include vaccinations, secretase inhibitors and anti-inflammatory drugs (Behl and 
Moosmann, 2002).  
Symptomatic relief that is provided by approved AD pharmacotherapies are lost with time 
and the disease progresses despite continued treatment (Farlow et al., 2010). Table 1 below, 
shows some of the approved acetyl cholinesterase inhibitor (AChEI) drugs for symptomatic 




Table 1: Symptomatic drug treatments for Alzheimer’s disease 





affected by food 
Metabolism 
Donepezil (Aricept) Cholinesterase inhibitor 5-10† 1 No CYP2D6 
CYP3A4 
Rivastigmine (Exelon) Cholinesterase inhibitor 3-12 2 Yes Non-hepatic 
Galantamine (Reminyl; 
Reminyl PR*) 




Memantine (Ebixa) NMDA**-receptor antagonist 5-20 2 (one) No Non-hepatic 




Aβ fibrillar and oligomeric forms have been shown to have neurotoxic effects in vivo and in 
vitro consequently strategies to prevent the formation of or to lower levels of Aβ in the brain 
are anticipated to be of tremendous therapeutic benefit. There are several AD 
immunotherapies that are currently under research which include, direct immunization with 
synthetic full length forms of Aβ and the administration of modified Aβ fragments that may 
be conjugated to specific carriers in order to stimulate T- and β-cell lymphocytic immune 
responses and evade challenges that accompany intensifying a T-cell reaction precisely 
against Aβ (Morgan, 2006, Delrieu et al., 2012).  
 
Short peptides (<100 AAs) are the key regulators in a variety of biological activities because 
they offer high specificity associated with low toxicity and thus peptide beta sheet breakers 
(BSBs) have gained a lot of popularity because of these properties (Funke and Willbold, 
2012). Several peptide based inhibitors or BSBs of the Aβ self-aggregatory process have 
been reported (Pratim Bose et al., 2009). The first pentapeptide BSB was reported by 
Tjernberg et al. (1996). Since then, these pentapeptide BSBs have demonstrated their efficacy 
in vitro and in vivo (Hetényi et al., 2002). There are a total of 67 therapeutic peptides on the 
market today, 150 are in clinical phases and there is more than 400 in the pre-clinical trial 
stages (Funke and Willbold, 2012). Principally short N-methylated peptides analogous to 
parts of the hydrophobic central region (residues ~16-24) of Aβ have been used to design 
these anti-amyloid factors or BSBs with attractive pharmacological properties (Pratim Bose 
et al., 2009, Sigurdsson et al., 2000). Figure 1.5 shows research directions and strategies in 






While the central region of Aβ has attracted much attention, the C-terminal region has been 
far less explored despite the fact that this region forms intermolecular β-sheet contacts in Aβ 
fibrils and was previously proposed to be the kinetic determinant of the self-assembly process 
(Pratim Bose et al., 2009). More recently it was also demonstrated that peptides derived from 
Aβ positions 28-42 were efficient in protecting neurons from Aβ toxicity, again pointing to 
the importance of the C-terminal region (Pratim Bose et al., 2009).  
 
1.13    Poly - N - methylated Amyloid - β - Peptide (Aβ) C - terminal Fragments    
(MEPTIDES) 
In a recent study a novel compound Poly - N - methylated Amyloid - β - Peptide (Aβ) C - 
Terminal Fragments (MEPTIDES) (Figure 1.6) was shown to reduce Aβ toxicity in vitro and 
in Drosophila melanogaster. This study found that the C - terminal fragments (covering 
residues 31 - 42 or parts thereof) may be incorporated into the putative hydrophobic core of 
Aβ oligomers consequently disrupting it and thereby reducing its toxicity (Pratim Bose et al., 
2009). However whether this novel drug is equally effective in mammals to inhibit Aβ - 
induced toxicity remains unknown. 
 
Figure 1.5:  Research directions and strategies in the search for disease-modifying drugs  
APP denotes amyloid precursor 
protein,  
  , Aβ denotes beta-amyloid, and NFT neurofibrillary tangles (Chu, 2012).  
Secretase 
modulators 



















Figure 1.6: Diagram showing Molecular structure of MEPTIDES. Image adapted from Pratim 
Bose et al. (2009). 
1.14  Basis of the study 
As stated earlier, the prevention and/or retardation of progressive AD, will have substantial 
medical, social and financial benefit to the patient, family members and the entire health care 
fraternity. We hypothesized that MEPTIDES will reverse the neurotoxic effects of Aβ42 in vivo. 
 
1.14.1  Aims 
The aims of the present study were therefore to 
 Establish and characterize a rat model that may resemble some of the symptoms of 
AD; and to 














2.1  Materials and methods 
2.1.1  Reagents and materials 
Aβ42 peptides were purchased from DLD Scientific and MEPTIDES were synthesized by 
manual solid phase peptide synthesis on a Sieber resin with HATU as coupling reagent 
(Pratim Bose et al., 2009) by the University of KwaZulu-Natal Catalysis and Peptide 
Research Unit. OxiSelect
TM
 ZR RNA MiniPrep
TM 
kit was purchased from Zymo Research 
CORP. Nano-drop® ND-100 Spectrophotometer (Thermo Scientific, SA) was used for 
detection of RNA purity.  iScript™ cDNA Synthesis Kit (Bio- RAD, SA), primers designed 
and produced commercially (Inqaba, SA) were used to synthesize cDNA. Fast Start SYBR 
Green I, Gene-Amp 9700 Thermocycler from (Applied Biosystems, California, USA) and 
Light Cycler and software 4.1 (Roche Diagnostics) were used for qPCR caspase-3 gene 
amplification and analysis of results. OxiSelect
TM 
HNE Adduct Immunoblot kit (Cell Biolabs 
Inc) was used to measure 4HNE levels. Labotec Titramax 1000 orbital shaker was used to in 
all steps that required shaking. Odyssey CLx, blocking buffer, IRDye from (LiCOR 
Biosciences) were used in western blotting. Anti-rabbit IgG HRP-linked (Cell Signaling 
Technology) and Chemi-doc system used was from (Bio-RAD, SA). Leica CM 1100 cryostat 
was used to cut brain sections. MALDI-TOF Autoflex III
TM
 Speed MS, software Flex 
Imaging 3.0, ImagePrep station and Indium-tin-oxide (ITO) type I slides (Bruker Daltonics, 







2.1.2  Ethical clearance 
Ethical clearance was obtained from the University of KwaZulu-Natal Ethics Committee. The 
reference number is 048/13/Animal. Institutional guidelines for animal care were followed 
(Animal Ethics Committee of the University of KwaZulu-Natal, 2007). All efforts were made 
to minimize animal suffering and to reduce the number of animals used. 
 
2.1.3  Animals 
Fully grown male Sprague-Dawley (SD) rats (n = 40) weighing between 300 – 350 g (8/9 
weeks of age), at the beginning of the study, were used. The rats were randomly assigned to 4 
groups (n = 10 rats/group) and housed under standard lighting conditions (12 hour light/dark 
cycles) (Sipos et al. , 2007), lights on at 06:00, 25 
o
C room temperature, humidity of 70%, at 
the Biomedical Resource Unit, University of KwaZulu-Natal, Westville campus. Food and 
















2.2  Experimental design and timeline 
Study A 
                          











                            
 
 





2.3  Stereotaxic surgery 
On day 5, the rats were first given atropine (0.1 mg/kg, i.p.) and subsequently anaesthetized 
using sodium pentobarbital (60 mg/kg, i.p.). After full anaesthesia (the absence of hind paw 
reflex) was achieved, the head was shaved and the rat was placed in a stereotaxic apparatus 
(David Kopf Instruments, CA, USA). A midline sagittal incision was made on the scalp and 
the underlying tissue removed to expose the skull. Burr holes through which the injecting 
needles were pushed into the brain, were drilled through the skull at the following 
coordinates: Anterior - Posterior = -4.8 mm from bregma; Medio-Lateral = ±3.4 mm from the 
midline suture; and depth of 3.0 mm below the dura according to the Atlas of Paxinos and 
Watson (5
th
 Edition, 2005). Aβ42 (2 mM) or Tris buffer (TB 0.15 M) (Shin et al., 1997) was 
injected bilaterally into the dorsal hippocampus using a Hamilton syringe which had been 
pretreated with dimethyldichlorosaline to prevent the Aβ42 from adhering to the inner surface 
of the syringe, at a rate of 1 µl/minute for 10 minutes to deliver a final volume of 10 µl. A 
further 2 minutes was allowed for optimal diffusion of the drug into the brain. The burr holes 
were closed with bone wax and the wound was sutured and cleaned with iodine solution. 
Cellulose was used for the dressing of the wound (Purdue Frederic, USA). The rats were 
placed on a heating blanket to prevent hypothermia during surgery. They were returned to 
their home cages after full recovery from surgery. The rats were then given a 2-day recovery 
period. The rats were handled and weighed each day during this recovery time. Subsequent to 
the recovery period, on day 8, the rats underwent spatial learning and memory tests in the 











2.4.  Learning and Memory tests 
 
 
                        Figure 2.2: Diagram showing Morris Water Maze tank. 
The Morris water maze is a circular tank/maze 1 m in diameter with 4 imaginary quadrants. 
The level of usually opaque water (temperature between 22 - 25°C, to minimize hypothermic 
stress of the rat) was just high enough to cover the top of a clear Perspex platform (10 x 10 
cm wide and 20 cm high). The platform was placed in one of the quadrants, while the rat was 
placed in any of the other 3 quadrants. The rat was given 2 minutes to find its way to the 
platform. If not, the rat was gently guided to the platform during training after the 2 minutes 
had expired, and once on the platform the rat was given a maximum 15 seconds to familiarize 
itself with the position of the platform within the maze. There were 3 different starting 
positions, selected pseudo-randomly, at the borders of the quadrants in the tank. The rationale 
of the test is that the animal needs to find the platform using its memory of constant spatial 
cues placed around the maze. 
There were 3 training sessions, done on 3 consecutive days, with a pre - i.c. injection test on 
the 4
th
 day, following the final training session. The post-injection tests started 2 days after 
the i.c. injections of either TB or Aβ42. On day 8, post-lesion test 1 was performed. On days 9 
and 10, post-lesion tests 2 and 3 were carried out and the rats also received a MEPTIDES or 
saline injection (i.p.) after each test. The parameter that was recorded was the time taken for 
the rat to reach the hidden platform during all trials and tests. The rats were sacrificed on day 
14 by decapitation. 
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2.5  Sacrifice 
After completing the behavioural experiments, the animals were decapitated on day 14 
(between 10 am and 1 pm). Three whole brains from the MEPTIDES-treated Aβ42 and TB 
groups were rapidly removed from the skull placed in containers and gently immersed in 
liquid nitrogen until frozen. The brains were slowly immersed in the liquid nitrogen in order 
to preserve the morphology of the brain tissue. The hippocampus was dissected out of fresh 
brains in all the other the animals. Dorsal and ventral hippocampi were weighed, placed in 
Eppendorf vials and snap frozen in liquid nitrogen. The samples were then stored for a 
maximum of one month in a biofreezer at a temperature of -73 ˚C for further biochemical 
analysis. 
 
2.6 Biochemical Assays 
2.6.1  Real time PCR 
Total ribonucleic acid (RNA) was isolated from previously stored snap frozen hippocampal 
tissue. The hippocampal tissue weighing between 20-50 mg was homogenized in 400 µl of 
RNA lysis buffer using a sonicator (12000 Hz for 10 seconds). The RNA was extracted as per 
manufacturer’s instructions. The purity of the RNA was determined using a Nano-drop® 
ND-100 Spectrophotometer with the purity of RNA determined by the absorbance ratio at 
260 nm/280 nm. RNA was considered pure if the absorbance ratio ranged between 1.7 and 
2.5.  The isolated RNA was used to synthesize cDNA using the iScrip™ cDNA Synthesis 
Kit, as per manufacturer’s instruction. The RNA was converted to cDNA using the Gene-
Amp 9700 Thermocycler, with the following parameters: melting point 25 °C for 5 minutes, 
40 °C for 30 minutes, 85 °C for 5 minutes and hold at 4 °C.  The cDNA was then stored at –
20 °C until further analysis. The primers and their sequence are shown in Table 2. The 
expression of caspase-3 (C3) gene was subsequently assessed using a Light Cycler. The Light 
Cycler-master mix consisted of the following: 5.4 µl water, 1.6 µl MgCl2 (3 mM), 1.0 µl 
forward primer (1.0 µM), 1.0 µl reverse primer (1.0 µM), 1.0 µl Fast Start SYBR Green I, 
and 1.0 µl cDNA. RNA was quantified using the Light Cycler under the following PCR 
conditions: one cycle consisted of 95 °C for 10 minutes followed by 45 cycles at 95 °C for 15 
seconds, 60 °C for 1 minute and 72 °C for 10 seconds using a single fluorescence 
measurement (Mackraj et al., 2008, Zhu et al., 2011). This was followed by a final cooling 
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step to 40 °C. A dilution series of C3 gene and GAPDH amplicons were used to construct a 
standard curve. Quantitative analysis of the data was performed using Light Cycler software 
4.1. Melting curve analysis was done to detect the presence of a single specific product. 
 
Table 2. Sequences of primers for real-time qPCR (Inqaba, SA) 
Target gene Primers (5′-3′)    (nt
1
)          PP
2 




25 1216-1240 25 








2.6.2  ELISA 
TNF-α was quantified using a sandwich ELISA from previously stored snap frozen 
hippocampal tissue. The hippocampal tissue of 5 animals per group (Aβ42, TB) weighing 
between 20-50 mg was homogenized in 600 µl of RIPA buffer (see Appendix B). 
Homogenates were centrifuged twice at 3578 g for 10 minutes at 4 
o
C. Supernatant was 
collected and protein concentration determined using the Bradford method (see Appendix A 
for standard curve and Appendix B Bradford method protocol) (Kruger, 2009). The protein 
lysate was stored at -80 °C after protein determination and standardization of protein 
concentration. Sample supernatant (diluted 5-fold) or protein standard (100 µl) were added to 
each well and incubated for 2.5 hours in the dark at 4 
o
C with gentle shaking on an orbital 
shaker. Plates were then washed 4 times with 1 X wash buffer (300 µl) using a multichannel 
pipette. Biotinylated anti-rat TNF-α antibody (100 µl) was added to each well and incubated 
for 1 hour at room temperature with gentle shaking on an orbital shaker. Plates were washed 
again 4 times with 1 X wash buffer (300 µl) using a multichannel pipette. HRP-conjugated 
streptavidin (100 µl) was added to each well and incubated for 45 minutes at room 
temperature with gentle shaking on an orbital shaker followed by 4 washes with 1 X wash 
buffer (300 µl) using a multichannel pipette.  Hundred microliters of 3, 3’, 5, 5’-
tetramethylbenzidine (TMB) substrate solution was added for 30 minutes at room 
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temperature in the dark with gentle shaking.  Finally, 50 µl of stop solution was added to each 
well and absorbance was measured at 45nm on a plate reader. 
 
2.6.3 Western Blotting 
The hippocampal tissue of 4 animals per group from the Aβ42, TB, MEPTIDES-treated Aβ42 
and MEPTIDES-treated TB groups, was homogenized in 600 µl of RIPA buffer (see 
Appendix B). Homogenates were centrifuged twice at 3578 g for 10 minutes at 4 
o
C. 
Supernatant was collected and protein concentration determined using the Bradford method 
(Appendix B) (Kruger, 2009).The protein lysate was stored at -80 °C. After protein 
determination and standardization of protein concentration, equal amounts of protein samples 
(40 µg) were diluted at a ratio of 1:2 with Bio Rad sample buffer (Appendix B). The mixture 
was heated at 95 °C for 5 minutes. The electrophoresis apparatus was set up and filled with 
running buffer (Appendix C). The protein samples were loaded onto the gel (30 µg protein in 
each well). (Note: The volume of protein samples varied to obtain similar amount of protein 
in each well). The samples were run on the SDS-PAGE gel at constant 200 Volts and 
fluctuating current (between 1 - 400 mA) for 45 to 50 minutes or until the bottom most 
marker band reached the bottom of the gel. Proteins separated on the gels were then 
transferred to nitrocellulose membranes using the traditional transfer method, with constant 
current (400 mA) and variable voltage (between 1 - 250 V). Transfer required 60 minutes 
with this method. The membranes were subsequently blocked in non-fat milk (Appendix C) 
or blocking buffer (LiCOR Biosciences), for 2 hours. Membranes were then incubated 
overnight at 4 ˚C with either C3 or 4HNE primary antibody in 0.2 % Tween 20 in Tris 
buffered saline (TBS-T)/blocking buffer (1:1000), after which they were washed three times 
(5 minutes each wash) with TBS-T. The membranes were washed with 0.2 % Tween 20 in 
Phosphate buffered saline (PBS-T) if they were going to be viewed on the Odyssey CLx. The 
membranes were then incubated with anti-rabbit IgG HRP-linked or IRDye antibody as the 
secondary antibody (1:10000 or 1:150000 respectively) for 2 hours and washed twice with 
TBS-T or PBS-T and finally with TBS or PBS. Membranes viewed on the Odyssey CLx were 
viewed immediately after the final wash step. The chemiluminescence peroxidase substrate-3 
reagents were added to the membranes that were viewed on the Chemi-doc system. 




2.6.4  MALDI -TOF 
Previously stored whole brain samples of naïve control, and MEPTIDE-treated TB- and 
Aβ42-injected rats were sectioned using a cryostat (Leica CM 1100) into 10 µm thick sections 
and were placed onto chilled ITO coated MALDI TOF slides. The sections were then 
desiccated for 24 hours to remove any air bubbles.  
 
2.6.4.1  MALDI IMS matrix conditions  
For manual spotting, a-cyano-4-hydroxycinnamic acid (CHCA) was prepared in 50:50:0.1 
acetonitrile (ACN)/H2O/trifluoroacetic acid (TFA) under saturated matrix conditions. The 
drug (MEPTIDES) standard was mixed (1:3) with CHCA matrix solution and 0.5 ml were 
placed onto a MALDI target (steel plate) or a control tissue for analysis.  Matrix solution 
without the analyte was placed on tissue sections as control to check for matrix derived peaks 
interfering with the mass of the drug. 
For the imaging MALDI MS experiments, the tissue sections were coated with CHCA matrix 
solution using an automatic spraying device (Image Prep, Bruker Daltonics).  The Image Prep 
instrument deposits matrix solution onto the tissue in a controlled manner.  Briefly, a matrix 
aerosol is created by vibrational vaporization under controlled conditions with all droplet 
diameters ≤ 50 μm and an average droplet size of ≈ 20 μm.  A modified customized method 
was used for matrix application using the ImagePrep instrument.  The parameters for 
incubation time, wetness and matrix thickness were optimized to get the best spectra possible 
without delocalization of drug or endogenous compounds on the tissue.  The thickness of the 
matrix layer was monitored by the output from the optical sensor.  In short, the method 
contained four identical phases in which a matrix layer corresponding to 0.3 V was added by 
repeating a spray cycle of 2.5 s followed by 10 s incubation time and 90 s of drying time 







2.6.4.2        MALDI IMS detection limits and MS/MS verification 
The range of detection was investigated by applying different concentrations of the 
MEPTIDES onto a control brain section. The MEPTIDES was mixed (1:3) with matrix 
solution and the different amounts of the analyte applied to the tissue in a total volume of 0.5 
μl. The matrix spots were analyzed in reflectron mode collecting 200 shots per spot. Using 
MS mode, the peptide was detectable down to 1 ng and the signal response was 8 arbitrary 
units (au). The MEPTIDES standard was also analyzed in MS/MS mode using a LIFT 
method. The LIFT method was calibrated on the CHCA matrix peak of 379.1 Da and its 
fragments. The same method was used to perform MS/MS directly on naïve control, 
MEPTIDES-treated TB-injected and MEPTIDES-treated Aβ42-injected brain tissue and 
spectra generated were compared. Using the MS/MS mode, the MEPTIDES was detectable 
down to 1 ng. 
MS experiments were carried out using the AutoFlex III MALDI-TOF MS equipped with a 
solid-state Smartbeam laser operating at 200 Hz. The MS spectra were acquired in positive 
reflectron mode. For the initial analyses of the manually deposited spots, spectra consisting of 
1000 laser shots were acquired in bundles of 5 x 200 shots and data were collected between 
m/z 200 - 800 Da. Prior to analysis the MS method was calibrated using a standard peptide 
mix (Bruker Daltonics, Germany) and the matrix cluster peak from CHCA at m/z 379.1 Da. 
The MS/MS experiments were performed using a LIFT method optimized for the 
MEPTIDES by specific tuning of the timing of the LIFT cell and of the precursor ion 
selector. 
The software Flex Imaging 3.0 was used to set up the acquisition of the imaging experiments.  
The imaging MS experiments were performed by collecting spectra (200 shots) at a 
resolution of 200 μm in the same m/z range as above. 
The spectra were baseline subtracted (Convex hull) and smoothed (Savitzski golay) in the 
processing software during acquisition. In MS/MS mode, all spectra were normalized against 
root mean square (RMS) to reduce the influence of matrix hot spots. Here, we define the 
RMS as the root mean square of all spectra in the mass range analyzed. In this mode, both 
fragments and parent spectrum were acquired from each spot and 500 laser shots were 




2.7  Data presentation 
All results are presented as mean ± SEM. Software program Graphpad Prism (version 5.0, 
San Diego, California, USA) was used to analyze all statistical data. Data were subjected to 
either ANOVA with repeated measures where appropriate, followed by Bonferroni's posthoc 
test or non - parametric methods that included the Kruskal-Wallis and Mann-Whitney U tests. 
The t-test was used to test for a significant difference between two groups. The p value that 

























3.1  Behavioural results 
All rats were subjected to three days of learning trials and a pre- i.c. injection test was 
performed on day 4. The rats then received bilateral injections (10 μl, i.c.) of either Tris 
buffer (TB 0.15 M) or Aβ42 (2 mM) directly into the dorsal hippocampus. A 2-day period of 
recovery was allowed subsequent to the i.c. injections. The rats then underwent post- i.c. 
injection tests in the same MWM to determine the integrity of memory of the rats. All rats 
showed good learning ability before the i.c. injections (this was when trial 1 was compared to 
the pre- i.c. injection test using repeated measures ANOVA of the latency to reach the hidden 
platform), see Appendix A.  
The ANOVA showed that there were significant differences between groups (F (3, 36) = 4.00, 
p = 0.01, Figure 3.1 n = 10/group). Bonferroni's posthoc test showed that there was a 
significant difference in time taken to find the hidden platform in the MWM when the Aβ42 
pre-injection test was compared to Aβ42 post-injection test (18.20 ± 7.28 vs 49.60 ± 10.22, p 
< 0.05). The time taken to find the hidden platform by the Aβ42 group post- i.c. injection of 
Aβ42 was also significantly different from the TB post-injection test (49.60 ± 10.22 vs 16.10 
± 4.22, p < 0.05), (Figure 3.1). 
Sixty percent of the rats in the TB-injected group showed decreased time to reach the hidden 
platform vs 80 % of the rats in the Aβ42-injected group who showed an increased time to 
reach the hidden platform in the MWM when the post- i.c. injection test was compared to the 
pre- i.c. injection test of the same rats in their respective groups (Figure 3.2 A and B).   
The first aim of the present study was to establish and characterize a rat model that may 
resemble some of the symptoms of AD. We now had face validity through the MWM 
behavioural results and we were confident that a single bilateral i.c. injection of Aβ42 (2 mM) 
into the dorsal hippocampus impaired spatial learning and memory in adult male SD rats. 
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Several hypotheses of mechanisms of the neurotoxic effects of Aβ42 exist; we investigated 
inflammation, oxidative stress and apoptosis to test these hypotheses in our model. 
 
3.2  TNF-α ELISA results 
Literature suggests that one of the earliest disruptions that occur in the brain following Aβ42 
aggregation is the upregulation of inflammatory cytokines. TNF-α is one of the cytokines that 
has been observed to be upregulated in AD patients following Aβ aggregation (Johnstone et 
al., 1999, Akiyama et al., 2000). We performed an ELISA to determine the levels of TNF-α 
in the dorsal hippocampi of our TB- vs Aβ42-injected rats for validation of these previous 
findings in the present rat model of AD. The linear range for the ELISA is indicated in 
chapter 2 (2.5.2 ELISA). The t-test analysis of hippocampal TNF-α levels did not show any 
significant difference (5190 ± 186.70 vs 5032 ± 440.40, p > 0.05) when the TB- and Aβ42-
injected rats were compared (Figure 3.3). 
 
3.3 4HNE Western blot results 
It is unclear whether increased ROS production causes Aβ42 aggregation in the AD brain or 
vice versa, but there is certainty that disruption of the metabolic pathways of one of the ROS 
products has detrimental effects on the physiological homeostatic balance of an organism. 
We measured 4HNE levels in the dorsal hippocampi using Western blotting. 4HNE is a 
product formed when ROS react with the lipid bilayer of cell membranes. The aim was to 
determine whether oxidative stress was one of the mechanisms by which Aβ42 exerted its 
neurotoxic effects. The linear range and protein amounts used for the Western blots are 
indicated in chapter 2 (2.5.3 Western Blotting). The t-test showed that there was no 
significant difference between the Aβ42- and the TB-injected rats when the 2 groups were 












































































Figure 3.1: Graph showing time taken by TB-injected and Aβ42-injected rats to find the 
hidden platform in the MWM. The pre-injection test is the test before the i.c injection of TB 
or Aβ42 (10 μl, i.c., bilaterally) to create lesions similar to those observed in AD. The 
significant difference observed between the Aβ42 pre-injection test vs Aβ42 post-injection test 
(18.20 ± 7.28 vs 49.60 ± 10.22, *p < 0.05), shows a decrease in ability to recall the location 
of the platform in the rats injected with Aβ42. The significant different observed when Aβ42 
post-injection test was compared to TB pre and post-injection tests (49.60 ± 10.22 vs 23.30 ± 
8.07 and 49.60 ± 10.22 vs 16.10 ± 4.22, *p < 0.05), show that TB- i.c. injections did not 







Figure 3.2: Diagram showing percentage change in the time taken to find the hidden platform 
in the MWM when the post- i.c. injection test of the TB- and Aβ42-injected rats was 
compared to the pre- i.c. injection test of the same rats in their respective groups. The pre - 
injection test was taken as 100 % for all comparisons. Figure 3.2 A shows post-  vs pre- i.c. 
injection test of the TB-injected rats. Sixty percent of the rats in this group showed decreased 
time to reach the hidden platform vs the 40 % that showed an increased time to reach the 
hidden platform. Figure 3.2 B shows post-  vs pre- i.c. injection test of the Aβ42-injected rats. 
Eighty percent of the rats in this group showed an increased time to reach the hidden platform 






                  






                                             




















































Figure 3.3: Graph showing expression of TNF-α in the dorsal hippocampus of TB vs Aβ42-
injected rats. The t-test analysis of our TNF-α results did not show any significant difference 

























































Figure 3.4: Graph showing 4HNE Western blot results obtained for the dorsal hippocampi of 
Aβ42- vs TB-injected. The t-test analysis showed that there was no significant difference 













3.4  Behavioural results 
A similar trend was observed in the MEPTIDES-treated groups. The ANOVA showed a trend 
for the groups to be different from each other (F (7, 69) = 2.10, p = 0.05, Figure 3.5 n = 
10/group). Bonferroni's posthoc test showed a significantly increased time to find the hidden 
platform in the Aβ42 post-injection test 1, which is the first test before i.p. injection of 
MEPTIDES, compared to the Aβ42 pre-injection test (17.60 ± 4.24 vs 56.00 ± 12.41, p < 
0.05). This time was significantly reduced 24 hours after the first MEPTIDES i.p. injection in 
the same group (56.00 ± 12.41vs 21.50 ± 5.27,
 
p < 0.05), (Figure 3.5). 
  
3.5  C3 qPCR results  
There is extensive evidence to suggest that aggregation of Aβ42 in susceptible brain regions 
causes cell death (Loo et al., 1993, Awasthi et al., 2005) which leads to a decreased number 
of functional synapses. In the cerebral cortex specifically, this is associated with the dementia 
that is observed in AD patients. One of the mechanisms of cell death caused by Aβ is through 
activation of the caspase pathway (Cetin, 2013, Awasthi et al., 2005). We performed C3 gene 
qPCR and C3 protein Western blot analysis to test this theory in our model.  
There was a significant difference between groups in C3 gene expression revealed by 
ANOVA (F (3, 12) = 13.14, p = 0.0004). Bonferroni's posthoc test showed a significant 
upregulation of the C3 gene when the Aβ42-injected rats were compared to TB-injected rats 
(2.54 ± 0.45 vs 1.155 ± 0.11, p < 0.05). Notably, C3 gene expression decreased significantly 
to baseline levels when Aβ42-injected rats were compared to MEPTIDES-treated Aβ42-







3.6 C3 Western blots results 
Western blot results for C3 protein levels in dorsal hippocampal tissue of TB-injected, Aβ42-
injected, and MEPTIDE (2 mg/kg)-treated rats are shown in Figure 3.7 A and B. The linear 
range and protein amounts used in the Western blot are outlined in chapter 2 (2.5.3 Western 
Blotting). The t-test analysis of TB- vs Aβ42-injected rats did not show any significant 
difference in the dorsal hippocampal C3 protein levels (1.38 ± 0.09 vs 1.55 ± 0.27, p > 0.05), 
(Figure 3.7 A). The t-test analysis of the MEPTIDE (2 mg/kg)-treated TB- vs Aβ42-injected 
rats also did not show any significant difference when the 2 groups were compared (0.19 ± 
0.04 vs 0.11 ± 0.01, p > 0.05), (Figure 3.7 B).  
 
3.7  MALDI TOF MS results 
MALDI TOF MS was performed on brain samples that were from the TB-injected + 
MEPTIDES-treated rats vs Aβ42-injected + MEPTIDES-treated rats to determine whether 
MEPTIDES cross the BBB and their abundance in the brain. Optimization was first done by 
spotting the MEPTIDES on the metal target plate (Bruker Daltonics, Germany) and a naïve 
rat brain (see Appendix D). The different methods used to obtain spectra are outlined in 
chapter 2 (2.5.4.2 MALDI IMS detection limits and MS/MS verification). Na
+
 adducts of 




 adducts of fragments (674.12 ± 0.2 % m/z and 




 adducts of the fragments are 
indicated by a peak at 712.41 ± 0.20 % m/z (see Appendix D).  The m/z values obtained from 
the optimization results were used to analyze experimental brain tissue. There was a  greater 




 adduct of  the  fragments in the MEPTIDES-treated Aβ42-injected 
rat brain (Figure 3.8 C) when it was compared to the MEPTIDES-treated TB-injected brain 
(712.41± 0.20 % m/z) (Figure 3.8 B). This peak was not observed in the control naïve brain 







































































































































Figure 3.5: Graph showing time taken by MEPTIDES-treated TB-injected and Aβ42-injected 
rats to find the hidden platform in the MWM. The significant difference observed between 
the pre-injection test vs the post-injection test 1, which is the first test before i.p. injection of 
MEPTIDES in the Aβ42-injected group (17.60 ± 4.24 vs 56.00 ± 12.41, *p < 0.05) shows a 
decrease in ability to recall the location of the platform in the rats injected with Aβ42 and is 
similar to that of the Aβ42-injected group in Figure 3.1. This time however, was significantly 
reduced 24 hours after the first i.p. injection of MEPTIDES in the same Aβ42-injected group 
(56.00 ± 12.41vs 21.50 ± 5.27,
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Figure 3.6: Graph showing qPCR expression of the C3 gene in the dorsal hippocampal tissue 
of TB- and Aβ42-injected rats vs MEPTIDES (2 mg/kg)-treated TB- and Aβ42-injected rats. 
The i.c Aβ42 injection significantly increased the expression of the C3 gene when the Aβ42-
injected rats were compared to TB-injected rats (2.54 ± 0.45 vs 1.16 ± 0.11, *p < 0.05). Three 
injections of MEPTIDES (2 mg/kg, i.p.) over a 3-day period reversed the effect of Aβ42 on 
C3 gene expression when Aβ42-injected rats were compared to the MEPTIDES-treated Aβ42 









































































































































Figure 3.7: Graphs showing Western blot results for C3 protein levels in dorsal hippocampal 
tissue of TB-injected, Aβ-injected, and MEPTIDE (2 mg/kg)-treated rats. The t-test analysis 
of TB- vs Aβ-injected rats did not show any significant difference in dorsal hippocampal C3 
levels (1.38 ± 0.09 vs 1.55 ± 0.27, p > 0.05), (Figure 3.7 A). The t-test analysis of the 
MEPTIDE (2 mg/kg)-treated TB- vs Aβ-injected rats also did not show any significant 
difference when the 2 groups were compared (0.19 ± 0.04 vs 0.11 ± 0.01, p > 0.05), (Figure 
3.7 B).  
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Figure 3.8: Diagrams showing presence and abundance of MEPTIDES derived metabolites in 
the rat brain. Figure 3.8 A shows naïve brain. Figure 3.8 B shows TB-injected MEPTIDES-
treated rat brain. Figure 3.8 C shows Aβ42-injected MEPTIDES-treated rat brain. There was a  




 adduct of  the (690.04 ± 0.20 % and 674.13 ± 0.20 % m/z 
respectively) fragments in the MEPTIDES-treated Aβ42-injected brain (Figure 3.8 C) when it 
was compared to the MEPTIDES-treated TB-injected brain (712.41± 0.20 % m/z) (Figure 3.8 
B). This peak was not observed in the control naïve brain (Figure 3.8 A). The peak of interest 
(712.41± 0.20 % m/z) in all MALDI TOF MS results is indicated by the red line. The colour 






















The hippocampus is one of the limbic structures of the brain that plays a prominent role in 
cognitive processes such as learning, memory storage and spatial navigation. Not surprisingly 
it is also the brain area that is first to show damage in people suffering from cognitive 
impairments (Colombo and Broadbent, 2000) . Because of its devastating effects on the 
quality of life, rodent models have been developed to study the pathophysiology of disorders 
associated with abnormalities in learning and memory. 
The aims of the present study were to establish and characterize a rat model that may resemble 
some of the symptoms of AD and to evaluate the efficacy of MEPTIDES in vivo as a possible 
anti-AD drug.  
 
 In 2 studies we showed that a single i.c. injection of Aβ42 into the dorsal hippocampus 
increased the time taken by rats to find the hidden platform in the MWM test. Rats treated 
with MEPTIDES for 3 days after the intra-hippocampal Aβ42 injection found the platform in 
significantly less time than saline-treated rats, suggesting that the MEPTIDES had prevented 
the development of cognitive impairment in the Aβ42-injected rats. These findings are in 
agreement with previous studies where MEPTIDES were shown to reduce Aβ42-related 
neurotoxicity in vitro and in Drosophila melanogaster. Pratim Bose et al. (2009) Showed that 
di-or tri-methylation retarded the appearance of the β-structure of Aβ40 to 4-5 hours and for 
Aβ42 to 3 hours. Penta-methylation in contrast, completely prevented β-sheet formation by 
Aβ40 during the time period studied and delayed the appearance of Aβ42 β-sheet structure to 4 
hours. This suggested that the penta-methylated peptide is more efficient than the less 
methylated peptides in reducing formation of oligomers with β-sheet structure from Aβ40 and 
Aβ42. The penta-methylated peptide resulted in prolonged life span in Drosophila expressing 
Aβ42 but had no effect on the life span of wild type Drosophila treated with the penta-
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methylated peptide only (Pratim Bose et al., 2009), indicating that the mode of action of 
MEPTIDES is Aβ specific. These results influenced and motivated the current investigations 
to evaluate whether MEPTIDES have similar effects in mammalian systems. 
 
 
Behavioural results obtained in our study showed impairment in cognitive function of the 
Aβ42-injected rats when they were compared to vehicle (TB) injected rats in the Morris Water 
Maze (MWM). The Aβ42-injected rats took longer to find the hidden platform than vehicle-
injected rats. Interestingly our findings show approximately 70 % of the Aβ42-injected rats 
had difficulty completing the behavioural task during post-injection test 1, which is the test 
conducted 48 hours after the i.c. injection of Aβ42. We attributed this observation to the toxic 
activity of our Aβ42. These findings were significant in the context that 60 % of AD patients 
do not display cognitive deficit symptoms until the disease reaches severe stages (Findeis, 
2007). Our data confirmed the damaging effects of Aβ42, and highlights the devastating 
consequences it may have when left uncontrolled. However, we also recognize that AD is 
progressive in nature, and develops over many years. We therefore proposed that learning 
and memory deficits may not be the earliest sign of AD and that there may be other earlier 
markers of this detrimental disease.  
 
It is undoubtable that there is increased inflammation in the AD brain, and microglia 
contribute largely to this inflammation (Frautschy et al., 1998). The neuro-inflammatory 
response is therefore thought to be a secondary event subsequent to neuronal damage and 
degeneration. Inflammation in AD can be described as an upregulation of the inflammatory 
pathway that initially acts as a defense mechanism in response to increased Aβ 
aggregation/plaque formation in the brain (Simic et al., 2009). Strangely some cytokines 
including TNF-α, have been observed to increase plaque formation by altering APP 
processing via upregulation of  the β-secretase enzyme (Heneka and O'Banion, 2007), the 
rate-limiting enzyme in Aβ production (Cole and Vassar, 2007). This observation has been 
supported by studies indicating that the majority of the neurotoxic effects attributed to 
microglia are exerted by TNF-α in the AD brain (Heneka and O'Banion, 2007).  It has 
subsequently been speculated that TNF-α contributes to Aβ formation by causing sustained 
activation of the β-secretase pathway leading to Aβ production in a vicious cycle that 
ultimately causes cell death. In contrast TNF-α (Rogers et al., 1996) suggested to protect 
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against glutamate, ROS and Aβ neurotoxicity (Akiyama et al., 2000) in AD. The function of 
TNF-α may be concentration dependent as previous findings by Johnstone et al. (1999) which 
showed that Aβ40 and Aβ42 stimulated the release of chemokines and TNF-α in particular, to 
different extents. In our experiments we measured TNF-α using a sandwich ELISA and found 
no differences between control and Aβ42 rats. While our data appear to be contrary to those of 
others, the difference in findings may be a result of variations in experimental protocols.  
 
Increased production of ROS/free radicals leads to oxidative stress (Rosenfeldt et al., 2013) 
and ultimately apoptosis (Loo et al., 1993). Detection of these pathophysiological entities has 
been proposed as possible early biomarkers of AD. 4HNE is a major cytotoxic product from 
the class of α- and β-unsaturated aldehydes (Camandola et al., 2000) that is used as a marker 
for the occurrence and extent of lipid peroxidation (Schneider et al., 2001). We found that 
Aβ42 injection into the dorsal hippocampus did not alter 4HNE levels when compared to 
vehicle-injected control rats. The results of the present study therefore suggest that Aβ42 
injection into the dorsal hippocampus does not increase lipid peroxidation or oxidative stress 
in the rat brain. A study by Tsirulnikov et al. (2012) demonstrated that the deacetylation of 
mercapturic acids formed in the GSH conjugation metabolism of 4HNE is aminoacyclase 3 
(AA3) mediated in neurons and might initiate a chain of reactions leading to transformation 
of macromolecules that might participate in AD pathology. Although data from our study is 
in contrast to earlier studies reporting elevated levels of HNE-lysine adducts in AD 
hippocampal tissue sections and increased 4HNE levels in N2a/D9 cells (Sayre et al., 1997, 
Liu et al., 2013), it is supported by a study by Yao et al. (1999) which showed that lipid 
peroxidation does not mediate Aβ-induced cell death in PC 12 cells, and we postulate that 
this may in part responsible for the results of the present study. We cannot neglect vast 
differences in results associated with studies conducted in vitro and in vivo. We also believe 
that our experimental timeline for the animal studies was short for detectable differences in 
the 4HNE levels, as this marker is used to measure chronic oxidative stress.  
 
Caspases are a family of aspartate-specific cysteinyl proteases that are produced as 
catalytically inactive zymogens in cells (Chai et al., 2000). Executioner caspases-3 and -7 are 
a subset that cleaves specific substrates leading to alterations linked to apoptosis viz. 
chromatin condensation, DNA fragmentation, blebbing of plasma membrane, cell shrinkage 
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and ultimately cell death (Kasibhatla and Tseng, 2003). A biochemical feature associated 
with apoptosis is the expression of cell surface markers. The externalisation of 
phosphatidylserine (PS), a transmembrane glycoprotein of the phospholipid bilayer signals 
early phagocytosis of apoptotic cells with minimal compromise to adjacent and surrounding 
tissue (Bratton et al., 1997). Mitochondria play an important role in apoptosis, via the 
intrinsic apoptotic program. An initial crucial step for activation of the intrinsic apoptotic 
pathway is depolarisation of the mitochondrial membrane. Depolarised mitochondrial 
membranes occur as a result of the formation of mitochondrial permeability transition (PT) 
pores (Hirsch et al., 1997). Altered mitochondrial PT has been associated with various 
metabolic consequences such as halted functioning of the electron transport chain (ETC) with 
associated elevation in ROS and decreased production of cellular ATP (Wang, 2001). Bax, a 
pro-apoptotic protein of the Bcl-2 family, translocates from the cytosol to the outer 
mitochondrial membrane during apoptosis where it interacts with lipids and induces 
mitochondrial PT pores. Findings from Loo et al. (1993) showed severe surface blebbing, 
internucleosomal DNA fragmentation and shrunken neurons in cultured neurons 24 hours 
after exposure to Aβ. In another study by Awasthi et al. (2005), Aβ42 inhibited cell 
proliferation by approximately 80 % when compared to the control value, caused 
morphological changes to the cells in a dose- and time-dependent manner and caused 
apoptosis of IMR-32 cells through activation of caspase-8, -9 and -3. It was concluded in this 
study that Aβ42 activated initiator caspase-9, which is responsible for the activation of 
executioner C3 which causes apoptosis. In our study we observed an upregulation of the C3 
gene but no change C3 protein levels as a result of Aβ42 injection into the dorsal 
hippocampus compared to control vehicle-injected rats, using qPCR and Western blot. This is 
an interesting finding as it indicates increased gene transcription, without concomitant raise 
in protein level. A reasonable explanation for this observation may be that C3 turnover could 
have been accelerated. However the catabolic products of C3 have not been measured in the 
present study, so this explanation remains speculative. Nevertheless misalignment between 
gene transcription and protein synthesis is not new, since other researchers have experienced 
similar results. A study by Glanemann et al. (2003) showed that large increases in gene 
expression are not congruent with changes in enzyme activity. In another study,Ghazalpour et 
al. (2011) showed that levels of transcripts and proteins correlated significantly for only about 
50 % of the genes that they tested, with an average correlation of 0.27, and these correlations 
varied depending on the cellular location and biological function of the gene. Schwanhausser 
et al. (2011) Found that mRNA levels only explained around 40% of the variability in protein 
51 
 
levels, and protein abundance seemed to be predominantly regulated at the ribosome, which 
highlighted the importance of translational control.
 
Compared to translational control, protein 
stability seems to have a minor role in cellular protein abundance. Despite the vast literature 
available on misalignment between gene transcription and protein synthesis, we speculate 
that on such a closely regulated cascade like the C3 apoptotic cascade, it necessary to gain 
insight into the exact time point of the synthesis C3 protein in the pathway to be able to detect 
any subtle changes in its expression thereof.  We postulate that C3 protein may not have a 
direct impact in behavior from the present study; it is rather the changes in the abundance and 
distribution of the C3 and other proteins which are responsible for the behavioural changes 
that we observed. 
 
Promising, was the fact that MEPTIDES showed positive effects on behaviour and also 
down-regulated C3 gene expression increases induced by Aβ42. Pratim Bose et al. (2009) 
Found that MEPTIDES could be incorporated into the hydrophobic core of Aβ oligomers and 
thus prevent Aβ aggregation in vitro. This was proposed as the mechanism of action of 
MEPTIDES in lowering Aβ associated toxicity in vitro. Another study by Awasthi et al. 
(2005) where short peptide Aβ15-22, (8 AAs in length) were used, reported an inhibition of 
Aβ42 self-aggregation and hydrolytic activities in vivo. This decrease was accompanied by a 
corresponding decrease in Aβ-induced apoptosis. In a similar study by Sigurdsson et al. 
(2000), pentapeptides LPFFD suggested in vivo reversal of Aβ lesion in the rat brain. We 
postulate that the mechanism of action of MEPTIDES in vivo may be the same as its action in 
vitro and similar to what other previously reported short peptides of variable lengths of Aβ 
have shown. But it is not known whether MEPTIDES cross the blood brain barrier, and since 
methylation changes the chemical properties and confers rigidity to a compound which may 
affect its behaviour in several environments, it became necessary that we determined whether 
MEPTIDES did in fact cross the blood brain barrier in order to be able to attribute the effects 
that we have observed solely to the MEPTIDES. This was performed by MALDI-TOF MS. 
 





adduct (≈713Da) of the fragments that were previously obtained during the 
optimization process in the Aβ42 + MEPTIDES brain when it was compared to TB + 
MEPTIDES brain. We did not observe this peak in the control naïve brain. Silverberg et al. 
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(2003) Found that there was a coexistence of AD and adult-onset normal pressure chronic 
hydrocephalus (NPH) suggesting that AD and NPH are related and have a common 
physiological basis in cerebrospinal fluid (CSF) circulatory dysfunction and failure. CSF 
functions include buoyancy, acid base buffering and transport of molecules and 
micronutrients to and from the brain parenchyma. Failure of CSF to detoxify the brain may 
lead to aggregation of Aβ and other unidentified toxins (Silverberg et al., 2003). Endothelial 
receptors for Aβ disappear with age, this leads to increased parenchymal Aβ deposition since 
Aβ  has been observed to cross the BBB via capillaries and this happens to also be the 
primary route for its clearance (Silverberg et al., 2003). However, Aβ overproduction is not 
the only factor that determines whether Aβ will aggregate or not, particularly in late onset AD 
where Aβ overproduction does not seem to play a role (DeMattos et al., 2002). Other factors 
controlling local metabolism as well as clearance to plasma also seem to play a role 
(DeMattos et al., 2002). We postulate that it is these disruptions in CSF chemistry and BBB 
membrane integrity coupled with the Aβ specific nature of MEPTIDES (Pratim Bose et al., 
2009) that lead to greater penetrance of MEPTIDES into the Aβ42-exposed brain where it is 




















Substantial evidence exists that indicate Aβ to be one of the etiological factors in the 
development of AD. Since memory impairment is central to this neurological disorder, the 
present study focused on this characteristic symptom to investigate the possible therapeutic 
potential of a novel drug. The aims of the present study were to, establish and characterize a 
rat model that mimics the cognitive symptoms of AD and to evaluate the efficacy of 
MEPTIDES in vivo as a possible anti-AD drug. A single i.c. injection of Aβ42 (2 mM) was 
administered stereotaxically into the dorsal hippocampus of adult male SD rats and spatial 
learning and memory tests were conducted using the MWM. The rats showed deficits in 
learning and memory following intra-hippocampal injection of Aβ42, and these deficits were 
reversed by i.p. injections of MEPTIDES (2 mg/kg) over a 3 day period. Biochemical 
analysis of hippocampal brain tissue showed upregulation of the C3 gene in the Aβ42 rats. 
There was a downregulation of the C3 gene but no difference in C3 protein levels in the Aβ42 





the MEPTIDES fragments in the Aβ42-injected brain when compared to the vehicle-injected 
rat brain. The present study is the first study to document that MEPTIDES cross BBB and it 
is also the first study to document the in vivo effects of MEPTIDES. 
 
5.1 Conclusion 
Findings from this study showed that a single bilateral intrahippocampal injection of Aβ42 
induces deficits in cognitive function in adult male SD rats by upregulating the C3 driven 
apoptotic pathway. MEPTIDES administered intraperitoneally get into the brain parenchyma 
in order to attenuate Aβ42 induced behavioural deficits. The mechanisms, by which 
MEPTIDES do so, include the downregulation of the C3 cascade. Our study further suggests 
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Graphs showing the pre- and post-injection MWM results of the TB, Aβ42, TB + MEPTIDES 


































































































































WESTERN BLOT STANDARD CURVE


















Graph showing Western blot standard curve.  Standard samples OD range (0.221 – 1.901). 










Graph showing TNF-Alpha ELISA standard curve. Standard samples OD range (0.000 – 
1.125). Experimental tissue sample range (0.393 – 0.518) 
Appendix B  
 
     Western Blotting 
TNF-Alpha ELISA STANDARD CURVE


















Laemli Buffer system 
Stock solutions 
1. Acrylamide/Bis (30 %) 
a. 87.6 g acrylamide (29.2 g/100 ml) 
b. 2.4 g N’N’-bis-methylene-acrylamide (0.8 g/100 ml) 
Make to 300 ml with distilled water. Filter and store at 4°C in dark. (Up to 30 days 
maximum) 
2. 10 % SDS 
Dissolve 10 g of SDS in 90 ml distilled water with gentle stirring and make up to 100 
ml using deionised water. 
 
3. 1.5 M Tris-HCl, pH 8.8 
a. 27.23 g Tris base (18.15 g/100 ml) 
b. 80 ml distilled water 
Adjust pH to 8.8 with 6 N HCl. Bring total volume to 150 ml using distilled water 
after adjusting pH. Store at 4 °C. 
4. 0.5 M Tris-HCl, pH 6.8 
a. 6 g Tris Base 
b. 60 ml distilled water 
Adjust pH to 6.8 using 6N HCl. Bring total volume to 100 ml using distilled water 
after adjusting pH. Store at 4 °C. 
5. 10 % APS (must be prepared fresh each time) 
a. 100 mg ammonium persulphate 
b. Dissolve in 1 ml distilled water 
 
6. Sample Buffer (Stock) 
a. 3.55 ml distilled water 
b. 1.25 ml 0.5 Tris-HCl pH 6.8 
c. 2.5 ml glycerol 
d. 2 ml 10 % SDS 
66 
 
e. 0.2 ml 0.5 % Bromophenol blue 
Total voume 9.5 ml. Store at room temperature. 
To use: Add 50 µL β-mercaptoethanol to 950 µl sample buffer prior to use. Dilute 
the sample at least 1:2 with sample buffer and heat at 95 °C for 4 minutes.  
 
7. 10 x Running buffer (Stock) 
a. 30.3 g Tris base 
b. 144 g Glycine 
c. 10 g SDS 
Dissolve and bring total volume up to 1000 ml (1 L) with distilled water. Do no 
adjust pH with acid or base. Store at 4 °C. If precipitation occurs warm to room 
temperature before use. 
To use: Dilute 50 ml of the 10 x stock with 450 ml distilled water for each run. 
Mix thoroughly before use. 
 
8. 10 x transfer buffer (Stock) 
a. 30.0 g Tris Base 
b. 144 g Glycine 
Dissolve and bring total volume to 1 L with distilled water. Do not adjust pH with 
acid or base. 
To use: Dilute 50 ml of the 10 x stock with 350 ml distilled water and 100 ml 
methanol. Mix thoroughly before use. 
 
9. 10 x TBS 
a. 87.66 g Sodium chloride 
b. 12.11 g Tris 
c. 40 ml HCl 
Make up to 1000 ml using distilled water. Adjust pH to 8.0. Note: 10 x TBS can 
be made in larger volumes and stored for long periods. 
To use: Dilute 100 ml TBS in 900 ml distilled water and mix thoroughly. 
 
10. 1 x TBS-T 
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Dilute 100 ml 10 x TBS in 900 ml distilled water and add 1 ml Tween 20. Mix 
thoroughly. 
 
11. RIPA buffer 
a. 8.76 g NaCl 
b. 10 ml Tris pH 7.2 (1 M Tris) 
c. 10 ml 10 % SDS 
d. 1ml Triton X 100 
e. 10 g Na deoxycholate 
f. 10 ml 0.5 M EDTA 
Make up to 1 L using distilled water and filter well before use. The buffer can be 
aliquoted in Eppendorf vials and stored at -20 °C. 
 
 
12. Bradford’s reagent (protein quantification) 
a. 50 mg Coomassie Brilliant Blue G250 
b. 50 ml methanol 
c. 100 ml 85 % Phosphoric acid 
d. 850 ml distilled water. 
Dissolve 50 mg Coomassie brilliant Blue G250 in 50 ml methanol. To this add 
100 ml phosphoric acid. Now add 500 ml distilled water. Filter and remove 













Western Blotting (SDS PAGE) 
 
Prepare gels (resolving gel and stacking gel) of required percentage. 
Note: While allowing resolving gel to set, cover the surface with isobutanol 
 
For 10 ml of resolving gel.  














4% 6.1 1.3 2.5 0.1 50 5 
7% 5.1 2.3 2.5 0.1 50 5 
10% 4.1 3.3 2.5 0.1 50 5 
12% 3.4 4.0 2.5 0.1 50 5 
14% 2.7 4.7 2.5 0.1 50 5 
16% 2.1 5.3 2.5 0.1 50 5 
 
Note: Add APS and TEMED immediately prior to pouring the gel 
 
4% Stacking gel:  
30% Acrylamide/Bis – 1.3 ml 
0.5M Tris pH 6.8 – 2.5 ml 
10% SDS – 100 µl 
Distilled water – 6 ml 
10% APS – 100 µl 
TEMED – 10 µl 
Note: Adjust the volumes above accordingly to prepare different amounts of gels.  Add APS and 
TEMED immediately prior to pouring the gel. 
       Electrophoresis 
- Samples must be boiled at 95°C for 5 minutes prior to loading 
- Assemble the electrophoresis apparatus and fill in 1x running buffer 
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- Load approx 5 µl of the protein marker being used 
- Load up to 25 µl (20 µg) protein in each well. (Note: Amount and volume of protein varies 
according to protein concentration, requirement and capacity of the wells) 
- Run the gels at 200V (400 mA) for about 45 to 50 minutes or until the bottom most marker 
band runs to the bottom of the gels 
- Equilibrate the gels in transfer buffer for about 10 mins 
Transfer 
- Soak 2 pieces of extra thick (2.4 mm) filter paper per gel OR 6 pieces of thick filter paper (0.8 
mm) per gel in transfer buffer 
- If using nitrocellulose membrane, wet it in transfer buffer; if using a PVDF membrane, wet it 
in methanol or ethanol for 30 sec. Following this, wash the membranes for 1-2 mins in water 
and equilibrate in transfer buffer for 10 mins with agitation 
- Assemble the sandwich for transfer on the cassette base: wet filter paper pieces at the 
bottom; membrane; the gel; the remaining wet filter paper pieces. Using the blot roller 
remove air bubbles 
- Place the cassette lid over the base and secure the lid making sure the lid is tightly closed 
and electrical contacts fit closely into the slots in the base. 
- Slide the cassette into the bay. 
- Choose a standard SD protocol from the BioRad menu 
- Initiate run by pressing the navigation button that corresponds to A: RUN for the upper bay 
and B: RUN for the lower bay. 
- After run is complete place the membranes in methanol for about 30 seconds and dry on a 
tissue paper 
Note: Always handle membranes using tweezers 
Blocking 
- The membrane is blocked in milk (5g fat free milk powder in 100 ml TBS-T). Prepare desired 
volume of milk. 25-30 ml is sufficient to immerse one membrane 























Date of acquisition 2014-07-15T17:18:24.644+00:00 
Acquisition method name  
Spectrum type 
Parent ion mass for ms/ms spectra 
Precursor ion selector lower mass limit 
Precursor ion selector upper mass limit 
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Number of shots 
LIFT  
722.41  
4.696  Da 
4.696  Da 
false 3000  
Bruker Daltonics flexAnalysis 
Instrument InfoUser   BDAL@DE 
Instrument FLEX-PC 
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